Saleh Soloman, George Jacob, Kott Katharine A, Meikle Peter J, Figtree Gemma A
Cardiothoracic and Vascular Health, Kolling Institute of Medical Research, Sydney, NSW, Australia.
Faculty of Medicine and Health, University of Sydney, Sydney, NSW, Australia.
Front Cardiovasc Med. 2022 Jun 2;9:897106. doi: 10.3389/fcvm.2022.897106. eCollection 2022.
As a leading cause of mortality and morbidity worldwide, cardiovascular disease and its diagnosis, quantification, and stratification remain significant health issues. Increasingly, patients present with cardiovascular disease in the absence of known risk factors, suggesting the presence of yet unrecognized pathological processes and disease predispositions. Fortunately, a host of emerging cardiovascular biomarkers characterizing and quantifying ischaemic heart disease have shown great promise in both laboratory settings and clinical trials. These have demonstrated improved predictive value additional to widely accepted biomarkers as well as providing insight into molecular phenotypes beneath the broad umbrella of cardiovascular disease that may allow for further personalized treatment regimens. However, the process of translation into clinical practice - particularly navigating the legal and commercial landscape - poses a number of challenges. Practical and legal barriers to the biomarker translational pipeline must be further considered to develop strategies to bring novel biomarkers into the clinical sphere and apply these advances at the patient bedside. Here we review the progress of emerging biomarkers in the cardiovascular space, with particular focus on those relevant to the unmet needs in ischaemic heart disease.
作为全球死亡率和发病率的主要原因，心血管疾病及其诊断、量化和分层仍然是重大的健康问题。越来越多的患者在没有已知风险因素的情况下出现心血管疾病，这表明存在尚未被认识的病理过程和疾病易感性。幸运的是，许多用于表征和量化缺血性心脏病的新兴心血管生物标志物在实验室环境和临床试验中都显示出了巨大的前景。这些生物标志物已证明，除了广泛接受的生物标志物外，还具有更高的预测价值，并且能够深入了解心血管疾病广泛范畴下的分子表型，这可能有助于制定进一步的个性化治疗方案。然而，转化为临床实践的过程——尤其是在应对法律和商业环境方面——带来了诸多挑战。必须进一步考虑生物标志物转化流程中的实际和法律障碍，以制定策略，将新型生物标志物引入临床领域，并在患者床边应用这些进展。在此，我们回顾心血管领域新兴生物标志物的进展，特别关注那些与缺血性心脏病未满足需求相关的生物标志物。
